Share this Page:
Yesterday is was announced that theapproved for the adjuvant treatment of people with increased risk of their returning after surgery ( ). This is the first adjuvant to be approved for use on the NHS in Scotland.
is medication that is given in addition to surgery to try to prevent the from coming back. can be used to kill any remaining microscopic , or it can control the growth of any remaining .
This recommendation is based on the results from the phase 3 KEYNOTE-564 trial where adjuvantsignificantly reduced the risk of the returning by about one third (32%) compared to .
Rose Woodward, Founder of Action pembrolizumab the first adjuvant to be available on the NHS in Britain. This meets a great unmet need for these patients and reduces the stress and anxiety for the patients and their families.”, said: “Action are delighted that the SMC has approved as an for people with at high risk of returning following surgery. This approval has come hot on the tail of the NICE approval, making